



**INDO US**  
**BIO-TECH LIMITED**  
(AN ISO CERTIFIED COMPANY)  
CIN LO1122GJ2004PLC043550



Date: 9<sup>th</sup> April, 2024

To,  
**BSE LIMITED,**

**Subject: Response to Clarification on Price Movement of Indo Us Bio Tech Limited (Scrip Id: INDOUS Scrip Code: 541304) - Regulation 30.**

**Ref.: BSE- Indo Us Bio Tech Limited (Scrip Id: INDOUS Scrip Code: 541304 Corporate Announcement dated April 04, 2024.**

Thank you for your communication regarding the observed price movement of our security at the Exchange.

We understand the significance of compliance with Regulation 30 of the SEBI (LODR) Regulations, 2015 and assure you of our commitment to transparency and timely disclosure of all material information affecting the operation and performance of INDO US BIO TECH LIMITED.

At this point, we have reviewed our recent operations, financial performance, and any other material developments within the organization. As of the current date, there have been no undisclosed events or information that may have directly influenced the recent price behavior in our company's scrip.

Regarding the "significant movement in the price of our security" highlighted in your communication, we would like to provide clarification. Our analysis indicates that this movement may be attributed to market sentiment, the prevailing demand-supply dynamics for our scrip, and the involvement of various existing and potential investors in our shares. It's important to note that the company's management does not exert influence or control over activities occurring on the stock exchange platform. The price fluctuations observed are often a result of market forces and investor behaviors, wherein the company's role remains passive, devoid of direct involvement in these stock market activities.

However, to reaffirm our commitment to investor awareness and compliance, we will diligently reevaluate our recent activities and developments. Should any material information surface that could potentially impact the price behavior of our security, we will ensure prompt disclosure in adherence to regulatory requirements.

We will proceed to submit this response through the BSE listing center portal under the designated section of "regulation 30".

Please do not hesitate to contact us should you require any further clarification or additional information.

Thank you for your understanding and cooperation.

Yours sincerely,

**For INDO US BIO-TECH LIMITED**

**Mr. Jagdish Ajudia**  
**Managing Director**  
**(DIN: 01745951)**

